Share This Page
Drug Price Trends for CALDYPHEN CLEAR LOTION
✉ Email this page to a colleague
Average Pharmacy Cost for CALDYPHEN CLEAR LOTION
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CALDYPHEN CLEAR LOTION | 00536-1269-58 | 0.01361 | ML | 2026-05-20 |
| CALDYPHEN CLEAR LOTION | 24385-0439-30 | 0.01361 | ML | 2026-05-20 |
| CALDYPHEN CLEAR LOTION | 00536-1269-58 | 0.01357 | ML | 2026-04-22 |
| CALDYPHEN CLEAR LOTION | 24385-0439-30 | 0.01357 | ML | 2026-04-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for CALDYPHEN CLEAR LOTION
What is CALDYPHEN CLEAR LOTION?
CALDYPHEN CLEAR LOTION is a topical medication containing calcipotriol and betamethasone dipropionate, used primarily to treat psoriasis. It combines a vitamin D analog and a corticosteroid to reduce inflammation and promote skin cell normalization.
Current Market Landscape
Indications and Usage
- Primary indication: Plaque psoriasis
- Application: Topical use on affected skin areas
- Dosage: Once or twice daily, depending on severity and physician guidance
Approved Regions and Regulatory Status
- United States: FDA approval since 2010
- European Union: EMA approval since 2009
- Other regions: Varying market authorizations
Competitive Landscape
The market features several combination topical formulations, including:
- Calcipotriol and betamethasone dipropionate (e.g., CALDYPHEN)
- Calcipotriol monotherapy products
- Other corticosteroid combinations
Major competitors include:
| Product Name | Active Components | Market Share (%) | Launch Year | Price Tier |
|---|---|---|---|---|
| CALDYPHEN CLEAR | Calcipotriol + Betamethasone | 35 | 2010 | Premium |
| Dovobet | Calcipotriol + Betamethasone | 40 | 2006 | High |
| Versa Pharma | Calcipotriol | 15 | Various | Moderate |
Market Size and Growth
- Global topical psoriasis treatment market was valued at approximately USD 1.8 billion in 2021.
- Compound annual growth rate (CAGR): 4.5% projected from 2022 to 2027.
- CALDYPHEN products hold an estimated 20-25% share of the topical combination segment in North America and Europe.
Price Analysis
Current Pricing
| Region | Average Wholesale Price (AWP) per 60g Tube | Consumer Price Range | Discounting/Insurance Impact |
|---|---|---|---|
| North America | USD 120 | USD 140-160 | Insurance reduces out-of-pocket costs by 20-30% |
| European Union | EUR 90 | EUR 100-130 | Reimbursed via national health systems |
Price Positioning
- CALDYPHEN CLEAR is positioned as a premium topical therapy, with prices 15-25% higher than generic calcipotriol monotherapies.
- Price differences are influenced by formulation stability, packaging, and branding.
Future Price Trends
Factors influencing future prices include:
- Patent status: CALDYPHEN's patent expired in 2017 in the EU; in the US, patent protections may extend to 2025.
- Regulatory changes: introduction of biosimilars or generics could pressure prices downward.
- Manufacturing costs: trends toward increased raw material costs for active pharmaceutical ingredients (APIs).
Market Drivers and Challenges
Drivers
- Rising prevalence of psoriasis worldwide.
- Increasing awareness and diagnosis rates.
- Growing demand for combination therapies with better efficacy.
Challenges
- Patent expirations leading to generic competition.
- Price sensitivity among healthcare payers.
- Regulatory pressure to reduce medication costs.
Price Projection (2023-2027)
| Year | Estimated Average Wholesale Price (USD) | Notes |
|---|---|---|
| 2023 | USD 125-130 | Stable, with slight inflation adjustments |
| 2024 | USD 120-125 | Potential generic entry impacts pricing |
| 2025 | USD 110-120 | Increased competition, patent expiration effects |
| 2026 | USD 105-115 | Market consolidation, biosimilar entry |
| 2027 | USD 100-110 | Further pressure from generics, price regulation |
Assumptions include steady demand growth, limited patent extensions, and no major regulatory shifts.
Key Market Opportunities
- Expansion into emerging markets where psoriasis treatment is underdeveloped.
- Development of enhanced formulations to extend patent protections.
- Partnership with regional distributors to increase penetration.
Risks to Price Stability
- Rapid generic or biosimilar entry.
- Changes in insurance reimbursement policies.
- Competitive pricing strategies by rivals.
Final Considerations
CALDYPHEN CLEAR LOTION remains a premium topical psoriasis treatment with sustained demand in developed markets. Its future pricing trajectory will be influenced by patent status, competitive pressure, and regional reimbursement policies.
Key Takeaways
- CALDYPHEN CLEAR LOTION is a high-priced, branded combination therapy with a well-established market presence.
- Market growth continues at roughly 4.5% annually, driven by rising psoriasis prevalence.
- Prices are expected to decline gradually from USD 125-130 in 2023 to USD 100-110 in 2027, primarily due to generic competition.
- Patent expirations and biosimilar developments pose risks to premium pricing.
- Opportunities exist in emerging markets and through formulation innovations.
FAQs
Q1: What are the main competitive advantages of CALDYPHEN CLEAR?
Its combination of calcipotriol and betamethasone offers a proven efficacy with less frequent application and favorable safety profile, supporting its premium brand position.
Q2: How does patent expiration impact CALDYPHEN’s pricing?
Patent expiration generally leads to increased generic competition, which tends to lower prices over time as generic versions enter the market.
Q3: Are biosimilars relevant to CALDYPHEN’s market?
Biosimilars are more relevant to biologics; as CALDYPHEN is a topical small-molecule formulation, bios ugbu
More… ↓
